ASX Announcement

26 February 2021

Jett Foundation 4th Annual Rare Disease Day

Antisense Therapeutics Limited ("ANP" or "the Company") is proud to be supporting the US-based Jett Foundation's Rare Disease Day Conference on Friday 26 February 2021 (2:00-3:30 PM ET) and to have Dr Gil Price, ANP's US-based Consultant Medical Director attend the event on behalf of the Company to engage with patients and families as well as industry participants.

Jett Foundation aims to extend and enrich the lives of individuals affected by Duchenne muscular dystrophy (DMD) and other neuromuscular disorders. It seeks to fulfil this mission by partnering with individuals and families through empowering educational programming, transformational direct service experiences, and by accelerating the development of life-changing treatments.

More than 60% of the patients and families served by Jett Foundation are non-ambulatory, representing thousands of families in the United States. Many of Jett Foundation's direct-service programs, including Camp Promise and Jett Giving Fund, are specifically targeted to families with non-ambulatory boys as they often need more assistance and have fewer options for support than younger children. ANP's lead drug ATL1102 recently delivered highly promising clinical results in non-ambulatory patients with DMD and is currently preparing for the conduct of the Phase IIb study in Europe planned to be launched in 2H21.

Jett Foundation's Rare Disease Day Conference (https://www.jettfoundation.org/rare-disease-day) provides an opportunity for industry partners to hear directly from DMD community to gain a better understanding and insight into current issues and themes, conflicts and challenges faced, and the overall burden of disease that one experiences with COVID-19 and Duchenne muscular dystrophy.

Mark Diamond CEO of Antisense Therapeutics said: "We look forward to expanding our engagement with US-based DMD community members, clinicians, and industry partners as we progress towards defining the regulatory pathway for ATL1102 in DMD in the US".

Authorised for release by the CEO.

For more information please contact:

Antisense Therapeutics
Mark Diamond
Managing Director & CEO
+61 (0)3 9827 8999
www.antisense.com.au

Investment Enquiries
Gennadi Koutchin
XEC Partners
gkoutchin@xecpartners.com.au
1300 932 037

About Antisense Therapeutics Limited (ASX:ANP | US OTC:ATHJY) is an Australian publicly listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development. The Company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne muscular dystrophy (DMD) patients and recently reported highly promising Phase II trial results. ATL1102 has also successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The

Company has a second drug, ATL1103 designed to block GHr production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.

About ATL1102 ATL1102 is an antisense inhibitor of CD49d, a subunit of VLA-4 (Very Late Antigen-4). Antisense inhibition of VLA-4 expression has demonstrated activity in a number of animal models of inflammatory disease. ATL1102 has also shown to be very effective in reducing inflammatory brain lesions in a patients with MS (Limmroth, V. et al Neurology, 2014; 83(20): 1780-1788) and recently delivered highly promising clinical results in patients with Duchenne muscular dystrophy (DMD) a rare and fatal muscle wasting disease where inflammation in the muscle leads to fibrosis and death of muscle tissue.